Novel EB (Epstein-Barr) virus EBNA1 epitope peptide and application thereof in diagnosis, treatment and prevention of EBV related diseases

A technology of EB virus and epitope peptides, applied in the direction of viral peptides, viruses, antiviral agents, etc., can solve the problems that cannot be fully applied to the immune prevention and treatment of EBV-related diseases, and achieve great application value and significance, and strong affinity Effect

Inactive Publication Date: 2016-06-22
深圳市中美康士生物科技有限公司
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, the epitopes discovered so far are not fully applicable to the immunoprevention and treatment of V-val subtype EBV-related diseases in East Asia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel EB (Epstein-Barr) virus EBNA1 epitope peptide and application thereof in diagnosis, treatment and prevention of EBV related diseases
  • Novel EB (Epstein-Barr) virus EBNA1 epitope peptide and application thereof in diagnosis, treatment and prevention of EBV related diseases
  • Novel EB (Epstein-Barr) virus EBNA1 epitope peptide and application thereof in diagnosis, treatment and prevention of EBV related diseases

Examples

Experimental program
Comparison scheme
Effect test

experiment example

[0052] 1. Experimental materials and instruments

[0053] AIMV medium;

[0054] Recombinant human IL-7;

[0055] Human recombinant IL-2 for injection;

[0056] PBS, without calcium and magnesium ions, cell culture grade;

[0057] EBNA-1 C-terminal sequence, 20aa overlapping peptides;

[0058] A series of truncated peptides;

[0059] DMSO;

[0060] Human IFN-γELISAKIT96T;

[0061] IFN-γsecretionassaycellenrichdetectkit;

[0062] MitomycinC, namely: mitomycin C;

[0063] PHA, namely: plant hemagglutinin;

[0064] BD Cytofix / Cytoperm TM PlusFixation / PermeabilizationKit

[0065] normal saline;

[0066] Various fluorescently labeled antibodies

[0067] centrifuge;

[0068] rotary mixer;

[0069] flow cytometer;

[0070] microscope.

[0071] 2. Experimental steps and methods

[0072] Step 1. Design and synthesis of candidate epitope peptides

[0073] Based on the most common HLA alleles (HLA-A, B, and DR loci) in Chinese, a series of polypeptides of about 20 amino ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides novel EB (Epstein-Barr) virus EBNA1 and application thereof in the diagnosis, treatment and prevention of EBV related diseases and discloses HLA-A*0201 limiting epitope peptide of EBNA1 in novel V-val subtype EB virus, this peptide having an amino acid sequence shown as GIALAVPQC; and discloses a method for preparing T-lympphocyte specifically reacting with EBNA1 by using the epitope peptide; and application of cells cultured by this method in the preparation of pharmaceutical compositions for preventing and treating EBV related diseases.The invention also relates to application of HLA-A*0201 limiting epitope peptide of the EBNA1 in the in-vitro diagnostic reagents and immunotherapy or preventive vaccines for EBV related diseases.Compared with corresponding sequences of common B95-8 viral strains, this epitope peptide has higher affinity with HLA-A*0201 molecules.

Description

technical field [0001] The invention relates to the field of immunotherapy, in particular to a novel Epstein-Barr virus EBNA1 epitope peptide and its use in the diagnosis, treatment and prevention of EBV-related diseases. Background technique [0002] EBV (Epstein-Barrvirus, Epstein-Barr virus) is the first time in 1964 that Epstein and Barr successfully established a strain of Burkitt African children's lymphoma cells through in vitro suspension culture, and observed herpes virus particles in the cell smears of the established strain with an electron microscope . EBV belongs to the herpesvirus gamma subfamily. EBV is widely infected in the population. According to serological surveys, most people have been infected in childhood. In healthy adults in developing countries, the infection rate of EBV exceeds 90%, and they remain latent for life after infection. In the vast majority of cases, there are no obvious symptoms after viral infection, and only a few cases can cause ac...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/05C12N5/0783A61K39/245A61P31/22
CPCC07K14/005A61K39/00C12N5/0636C12N2501/998C12N2710/16222C12N2710/16234
Inventor 王亚栋郎婧佟洁琼李晓祥黄卉刘根桃
Owner 深圳市中美康士生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap